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Background: Radioactive iodine (I-131) is routinely used for the treatment of differentiated thyroid cancer following
surgery. Drug-induced liver injury (DILI) is a leading cause of acute liver failure. Here we reported a rare case of diffuse
hepatic uptake (DHU) of radioactive iodine (I-131) induced hepatotoxicity in patient with I-131 ablation therapy after
thyroidectomy.
Case presentation: A 57-year-old woman was admitted due to jaundice, itching and dark urine with abnormally
elevated liver function. She has performed thyroidectomy followed by 100mci radioactive I-131 ablation therapy
21 days ago. The basic hepatic protection could not efficiently prevent disease progression. The patient was further
treated with methylprednisolone, the bilirubin and alanin aminotransferase were finally lowered back to normal in
the follow-up visit.
Conclusion: To the best of our knowledge, this is the rare description of DILI complications in thyroidectomy patient
due to I-131 ablation therapy. The patient responds to glucocorticoid therapy well, but not basic hepatic protection
treatment. Even though this is only a single case, it reminds physicians make DILI in early consideration when patient
present liver injury after I-131 ablation therapy.
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In recent years, it has become common to administer
radioactive I-131 as part of the therapeutic strategies in
patients with thyroid carcinoma following the surgical
procedure of total or partial thyroidectomy [1]. Ideally,
I131 treatment should only ablate residual micro/macro-
scopic tumor cells in the thyroid and/or distant metastasis
but not affect healthy tissues in the body. However, the
posttherapy scans frequently reveal diffuse I-131 uptake in
the liver [2-5]. This does not represent metastases in the
liver, which appear as discrete lesions. Drug-induced liver
injury (DILI), the term that describes abnormalities in liver
function tests related to medication intake, is a leading
cause of acute liver failure [6]. However, whether the dif-
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unless otherwise stated.therapy would induce DILI remains unclear in thyroid
cancer patient with thyroidectomy.
Here we report a rare case of DILI complications in
thyroidectomy patient due to I-131 ablation therapy.
There are three reasons make our case particularly all
the more worthy of attention. First, the radioactive I131
ablation is a routine therapy for thyroid cancer patient
after thyroidectomy; Second, I-131 ablation therapy
could present diffuse hepatic uptake; Third, DILI is the
leading reason for acute liver failure; I131 induced DILI
does not response to the basic hepatic protection.
Case presentation
A 57-year-old Chinese woman was admitted to our unit
with a one-week history of jaundice, itching and dark
urine. She denied history of liver disease, metabolic syn-
drome (obesity, diabetes, hypertension, dyslipidemia)
and alcohol exposure. She has been diagnosed as thyroid
cancer (papillary thyroid cancer) and performed total
thyroidectomy 3 months ago. The patient was furthers is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Emission Computed Tomography (ECT) 5 days after I131
treatment. As shown, I131 were uptaken mainly in the thyroid bed,
but also in the liver, stomach, oral and nasal cavity.
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ago (Emission Computed Tomography (ECT) image
taken 5 days after I131 therapy was shown as Figure 1).
Before starting I131 treatment, she had undergone ultra-
sonography of the liver and serum biochemical tests in-
cluding liver chemistry, with all results being within the
normal range.
On examination she presented with skin scratching,
yellowish discoloration of the skin and sclerae (eyes), no
edema, ascites nor encephalopathy were presented. La-
boratory tests were abnormal: elevated total bilirubin
(TB) = 131.1 μmol/L (7 folds above the upper limit of nor-
mal); Direct bilirubin(DB) = 82.1 μmol/L (10 folds in-
creased); alanin aminotransferase(ALT) = 370 μ/L (9 folds
increased); Aspartateaminotransferase(AST) = 189 μ/L (4.5
folds increased); gamma-glutamyltransferase (GGT)= 275 μ/L
(6 folds increased); alkalinephosphatase (ALP), serum albu-
min, total bile acid and international normalized ratio (INR)
were normal. Viral hepatitis (HAV(Ab), HBV (Ag/Ab),Figure 2 Enhanced Magnetic Resonance imaging(MRI) and Magnetic ResoHCV(Ab, RNA),HEV(Ab), EBV(Ab), CMV(Ab) and
HSV(Ab)), autoimmune serologies (antinuclear antibodies,
anti-smooth muscle antibody, anti-mitochondrial anti-
body/M2, anti-liver-kidney microsomal antibody, anti-liver
cell plasma antibody, anti-soluble liver antigen/liver–pan-
creas antigen) and serum tumor markers (AFP, CEA,
CA125, CA19-9, CA15-3, CA72-4, FER, FPSA, PSA, SCC,
NSE) were negative. No coagulopathy were observed. Iron
and copper status were normal. Abdominal ultrasound re-
vealed chronic diffuse hepatopathy, decreased size of gall-
bladder without gallstones or sludge and thicken gallbladder
wall. There is no pericholecystic fluid. The common bile
duct has a normal caliber. Enhanced Magnetic Resonance
Imaging (MRI) and Magnetic Resonance Cholangio-
Pancreatography (MRCP, Figure 2) were normal.
The patient was initially treated with basic hepatic
protection for 40 days, including glutathione, magne-
sium isoglycyrrhizinate, essential Nutrition, transmetil,
and/or tauroursodeoxycholic acid. The total bilirubin
was not efficiently controlled and kept increasing to
223.9 μmol/L 40 days later, even though the level of
AST and ALT were decreased. Liver biopsy was further
performed and the results showed swollen hepacytes,
predominant piecemeal necrosis within the lobules, ob-
vious canalicular and hepatocellular cholestasis [7]. The
portal inflammation, hepatocyte rosettes and fibrosis
were not detected (Figure 3). On the basis of Roussel
Uclaf Causality Assessment Method (RUCAM= 6 for this
patient, shown as Table 1) [8], it indicates the patient is
probable I-131 administration induced liver injury. There-
fore, the patient was further treated with methylpredniso-
lone (40 mg iv drip qd*14d followed by maintenance and
step-down withdrawal of oral methylprednisolone), the
TB and ALT/AST were finally lowered back to normal in
the end of follow-up visit (Figures 4 and 5). Considering
the safety and validity to easterners, 40 mg iv drip qd is
the standard initial dose in our institution for cholestatic
DILI patients, who are insensitive to basis hepatic protec-
tion. The maintenance time and gradual reduction regime
depend on the response of patients. Usually, the initial
dose will be hold for the first 2 weeks, and the dose will benance Cholangio Pancreatography (MRCP) of this patient were normal.
Figure 3 The representative images for Liver biopsy (A) and electron endoscopy(B) of this patient.
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ively controlled.
Discussion
Drug-induced liver injury(DILI) refers to liver injury
caused by drugs or chemical agents, which representsTable 1 Causality assessment of this patient
Criteria
1. Time to onset of the reaction Suggestive
2. Course of the reaction
3. Risk factor for drug reaction
4. Concomitant drugs
5. Non drug-related causes
6. Previous information on the drug
7. Response to readministration
Totalviral hepatitis-like symptoms, malaise, anorexia, nausea
and vomiting, right upper quadrant abdominal pain,
jaundice, acholic stools, and dark urine, as a special type
of adverse drug reaction [6,9,10]. DILI is one of the lead-
ing causes of acute liver failure in U.S.A., accounting for
around 13% cases of acute liver failure [11]. In China,Score
2 (5 to 90 days from the beginning of the initial I-131 treatment)
0 (no information )
1 (age of patient ≥55 years)
0 (None)
2 (None)
1 (Reaction published but unlabelled)
0 (Not done)
6
Figure 4 Line chart for the bilirubin level of this patient.
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acute liver failure. Exploring the risk of these events
poses a major challenge for drug safety.
The therapeutic value of I-131 ablation therapy after
total thyroidectomy has been used as an important com-
ponent in thyroid cancer management [12,13]. Based on
what is known so far, acute complications due to I-131
ablation therapy include transient parotitis and thyroid-
itis; reported chronic complications are amenorrhea,
pulmonary fibrosis, azoospermia, aplastic anemia, and
leukemia. The ablation-therapeutic I-131 induced DILIFigure 5 Line chart for the AST/ALT level of this patient.reaction has not been included either in I-131 product
label or well-known reports.
Even though the radioactive I-131 becomes mainly
toxic to thyroid cells that accumulate iodine from blood-
stream, it also could be biodistributed to whole body
and other organs. In total thyroidectomy patient, the
lower gastrointestinal tract, kidney, stomach, heart wall
and liver have been demonstrated to absorb relatively
high doses per unit of administered iodine activity [14].
In this case, the emission computed tomography (ECT)
I131 whole body scan demonstrated uptake mainly in
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nasal cavity 5 days after radioiodine treatment (Figure 1).
Besides the biodistribution of I-131 in thyroidectomy pa-
tient, the high dose of I-131 used for ablation therapy
might also be one of the reasons leading to DILI. Indi-
vidual dose of I-131 ranges from 2 to 4 mCi for diagno-
sis, and ranges from 5 to 10 mCi for hyperthyroidism.
However, it ranges from 75 to 150 mCi for therapeutic ab-
lation therapy, which is 15 times higher than treating be-
nign thyroid diseases and 35 times higher than monitoring
purpose. Navina et al have reported the hepatotoxicity after
I-131 treatment for 5 to 10 mCi each time in patients with
Grave’s disease [15], which warns us to pay more attention
to the possibility of hepatotoxicity induced by therapeutic
I-131 ablation therapy with much higher I-131 dose.
Conclusion
To our knowledge, there is rare description of DILI
complications due to I-131 ablation therapy in thyroid-
ectomy patient. The patient, who denies history of liver
disease, presents typical cholestatic damage manifestation
with short course of reaction to I-131 administration, and
responds to glucocorticoid therapy well, but not basic
hepatic protection treatment. This is only a case report
from one patient data, but it holds the significance to re-
veal the possibility of ablation I-131 therapy induced liver
injury. As an additional remarks, it reminds physicians
make DILI in early consideration when patient present
liver injury after I-131 ablation therapy.
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